This medicine is to be used only by or under the direct supervision of a doctor. Introduction on december 16, 2022, fda approved nadofaragene firadenovec (brand name adstiladrin), the first gene therapy for the treatment of bladder cancer It delivers a copy of the gene encoding ifnα2b to the bladder urothelium resulting in local expression of the ifnα2b protein for anti.
Sayume | Snipfeed
